1. HBW Insight
  2. >>Geography

FTC Considers Adding ‘Organic’ and ‘Sustainable’ Guidance In Environmental Claims Update

 
• By Eileen Francis

FTC asks for comments on whether it should consider issuing guidance on “organic” and “sustainable” claims in an update to its Green Guides. Commission will collect public comments for 60 days beginning mid-January for first update to guides in 10 years.

• Source: Shutterstock

The Federal Trade Commission again is considering providing guidance on “organic” and “sustainable” advertising claims in an update to its Green Guides for the Use of Environmental Claims, which would be the first in 10 years.

The FTC on 14 December announced it will collect comments on proposed changes to the guides – including to the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

AESGP Annual Meeting: European OTC Market Outlook ‘Very Positive’ Thanks To Prevention Trend

 
• By David Ridley

The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”